Wire · regulatory
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S. ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Scholar Rock has updated on regulatory progress for apitegromab, removing a fill-finish facility from U.S. and European applications under FDA guidance, maintaining FDA review on track for a September 30, 2026 decision, and aligning with Japan's PMDA to submit a New Drug Application by year-end 2026 without needing additional Japanese clinical studies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have clearer routes to market in the US, Europe, and Japan for SMA treatments as the FDA and PMDA accept streamlined processes; if you are developing rare disease drugs, plan submissions around these regulatory flexibilities.
◆ Coverage
1 source · 22 Aug 2026
◆ Related on Wire
◆ Topics